Enliven Therapeutics (ELVN) Other Non-Current Assets (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Other Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 83.49% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 83.49% YoY), and the FY2025 full-year result was $656000.0, down 90.86% from the prior year.
• Other Non-Current Assets rose to $1.2 million in Q1 2026, from $656000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $7.6 million in Q2 2024 to a low of $54000.0 in Q4 2022.
• A 5-year average of $3.6 million and a median of $3.7 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 13307.41% in 2024 and plunged 90.86% in 2025, its largest moves.
• Tracing ELVN's Other Non-Current Assets over 5 years: stood at $54000.0 in 2022, then soared by 7475.93% to $4.1 million in 2023, then soared by 75.38% to $7.2 million in 2024, then sank by 90.86% to $656000.0 in 2025, then soared by 81.1% to $1.2 million in 2026.
• Business Quant data shows ELVN's Other Non-Current Assets at $1.2 million in Q1 2026, $656000.0 in Q4 2025, and $7.1 million in Q3 2025.